GAITHERSBURG, Md., Dec. 16, 2019 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune...
Amgen Completes Acquisition Of Otezla® (apremilast) Differentiated Therapy Strengthens Amgen's Long-Standing Expertise in Inflammation PR Newswire THOUSAND OAKS, Calif., Nov. 21, 2019 THOUSAND...
Celgene Corporation (NASDAQ: CELG) announced today that following the completion of Celgene’s acquisition by Bristol-Myers Squibb Company (NYSE: BMY), Bristol-Myers Squibb and Celgene plan to...
Die Kombination aus Lenalidomid (REVLIMID®) und Rituximab (R2) hat das Potenzial, eine chemotherapiefreie Behandlungsoption für rezidivierte oder refraktäre Patienten mit follikulärem Lymphom zu...
Thermo Fisher Scientific Set to Join S&P 100; ServiceNow to Join S&P 500 PR Newswire NEW YORK, Nov. 19, 2019 NEW YORK, Nov. 19, 2019 /PRNewswire/ -- Thermo Fisher Scientific Inc...
NEW YORK, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that Exelon Corporation (Nasdaq: EXC), will become a component of the NASDAQ-100 Index® (Nasdaq: NDX), the...
By Stephen Nakrosis The U.S. Federal Trade Commission said Friday Celgene Corp. (CELG) agreed to divest its Otezla psoriasis treatment as a condition of the company's planned acquisition by...
By Colin Kellaher Celgene Corp. (CELG) on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Revlimid in combination with...
REVLIMID® and rituximab (R2) has the potential to become a chemotherapy-free combination treatment option for patients with follicular lymphoma who have relapsed or did not respond to previous...
Skyhawk Therapeutics annonce une deuxième entente de collaboration multicible avec Celgene pour découvrir et mettre au point de petites molécules novatrices qui modulent...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.